TLX... a Market's Overreaction or a Falling Knife?

So just for context to any investors happening upon this narrative...

What does Telix actually do?

Telix develops and commercialises radiopharmaceutical products; basically, precision imaging agents and therapeutics that help doctors find and (eventually) destroy tumours. Think of it less like a traditional pharma company and more like a GPS system for cancer. Their focus areas are urologic cancers, brain tumours, and solid tumours more broadly.

So why do I think a re-rating is on the cards in 2026/2027?

While yes, many are quick to point out Telix's far above-expected 2024 and 2025 performance, it does not mean that these products will necessarily be replaced or have declining usage in the near future. Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide - including key markets such as the U.S, Europe, China, Japan - with revenue figures of $803.8m (USD) in the 2025 Financial Year (within their already upgraded guidance range) provided for FY25, a cash balance of $141.9m (USD), and the potential growth of Gozellix as its launch into the U.S expands.

On top of that, they're vertically integrating manufacturing and distribution through a handful of acquisitions (RLS, ARTMS, Iso Therapeutics). Less reliance on third parties may mean better margins and more supply reliability over time. *In theory*.

And the therapeutics pipeline: prostate, kidney, glioblastoma and others - is where the real long-term upside lives if trials go well.

What's with the poor stock performance?

• Since March 4th 2025 TLX has experienced a -64.59% decline in value from $27.87AUD to $9.87 per share.

This could be attributed to various factors, including but not limited to:

• Complete Response Letter's received from FDA in response to TLX250-CDx and Pixclara approval (delayed timeline)
• General Healthcare sector underperformance
• Chairperson resignation(s)
• Profit-taking from investors

Risks to note...

R&D spend jumped to $157.1M (USD), and they're still utilising funds for manufacturing buildout.

There's also an SEC subpoena hanging over the therapeutic pipeline disclosures. It might amount to nothing, but it is something to note.

Pricing pressure in PSMA imaging is real too. Illuccix and Gozellix aren't operating in a vacuum, and if competitor dynamics shift unfavourably, margins on the core imaging business could get tightened further.

And RLS - their distribution arm - also ran at an operating loss in FY25. If Telix can't push enough of its own higher-margin products through that network, it drags on group margins.

Finally, the whole long-term thesis and higher growth estimates rest on clinical trials going well. ProstACT GLOBAL, LUTEON, IPAX BrIGHT are all examples to note... if any of these hit regulatory hurdles or ineffective results, the timeline for any additional lucrative therapeutic revenue gets pushed out significantly.

My final thoughts

TLX is a genuine high-conviction, high-risk setup. The infrastructure is being built, the commercial footprint is evident, the pipeline is real - but there are many heavy-weighting factors that could impact their 12-month outlook. Although you're paying for a lot of things going right simultaneously, the market has already repriced some of that optimism out with the stock sitting at $9.87...

Of course, do your own research (DYOR). Analyst consensus is $22.92, but the range runs from $17 bear to $32 bull, which tells you there's no concrete consensus on how right or wrong the story is. That spread is almost a story in itself...

Given the above, and Telix's FY26 Group Revenue guidance figure of $950-$970m (USD) and earnings expectations, my personal price target sits it at $18.00 over the next 12 months, representing a potential upside of ~82% from its current price. (Note this is not financial advice, DYOR GLTAH).